Kiniksa Pharmaceuticals International, plc (KNSA) Stock: Price, Forecast & Analyst Target
Kiniksa Pharmaceuticals International, plc (KNSA) — MoonshotScore 98/100 (Exceptional band), calculated Nov 18, 2026. Price $93.53 (-1.59%), as of the Nov 19, 2026 trading session; market cap $7.35B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 12.92× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Kiniksa Pharmaceuticals International, plc · KNSA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Kiniksa Pharmaceuticals International (KNSA)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $286M (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 4 of the last 8 reports
- Altman Z 18.02 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $93.53 | |
| Change on the day | -1.59% | |
| 52-week range | $37.02–$99.31 | |
| Market capitalisation | $7.35B | — |
| Price / earnings (trailing) | 66.51 | |
| Shares traded on the day | 426.2K | |
| Beta (volatility vs the S&P 500) | 0.08 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
As you have heard, we now expect ARCALYST to achieve over $1 billion in revenue in 2026 and we look forward to continuing to bring this blockbuster drug to more patients suffering from this debilitating disease.
Sanj K. Patel · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Kiniksa Pharmaceuticals International (KNSA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Kiniksa Pharmaceuticals International (KNSA), and what does it report?
Short answer
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. Kiniksa Pharmaceuticals International, plc (KNSA) is listed on NASDAQ. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 105 Piccadilly, London, W1J 7NJ, United Kingdom. It employs 366 people. In Q3 FY2026 it reported revenue of $286M and net income of $47M. The market values it at $7.35B.
What do the latest results show for Kiniksa Pharmaceuticals International (KNSA)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $286M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $285.97M Sep 30, 2026
- Latest quarter · R&D
- $32.79M Sep 30, 2026
- Latest quarter · SG&A
- $65.36M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $54.24M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $285.97M | $32.79M | $65.36M | $54.24M |
| Jun 30, 2026 | $243.60M | $40.90M | $63.87M | $27.19M |
| Mar 31, 2026 | $214.27M | $27.48M | $61.15M | $29.27M |
| Dec 31, 2025 | $202.13M | $34.64M | $56.77M | $19.77M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $285.97M Oct 27, 2026
- Latest report · revenue estimate
- $260.66M Oct 27, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 27, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 27, 2026 | $285.97M | $260.66M | $0.5600 | $0.3710 |
| Jul 28, 2026 | $243.60M | $226.49M | $0.3000 | $0.2995 |
| Apr 28, 2026 | $214.27M | $206.11M | $0.2700 | $0.1800 |
| Feb 24, 2026 | $202.13M | $200.81M | $0.1700 | $0.2900 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $286M | $47M | $0.56 (diluted) |
| Q2 FY2026 | $244M | $25M | $0.30 (diluted) |
| Q1 FY2026 | $214M | $23M | $0.27 (diluted) |
| Q4 FY2025 | $202M | $14M | $0.18 (diluted) |
What are the financial strengths and risks for Kiniksa Pharmaceuticals International (KNSA)?
Short answer
Cash and short-term investments were $568.76M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $47.28M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 18.02 · Piotroski F 6. Trailing ratios: ROE 17.3% · ROA 11.1% · current ratio 3.91 · earnings yield 1.5% · free-cash-flow yield 2.6%.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $47.28M Sep 30, 2026
- Previous quarter · operating cash flow
- $47.46M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $47.28M | −$180,000 |
| Jun 30, 2026 | $47.46M | −$660,000 |
| Mar 31, 2026 | $50.20M | −$160,000 |
| Dec 31, 2025 | $53.89M | −$630,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Kiniksa Pharmaceuticals International (KNSA)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027. Current published price targets run low $74.00 · high $115.00 · consensus $97.40 · median $99.00 against a quoted price of $93.53 (as of Nov 19, 2026).
What management is planning
How does Kiniksa Pharmaceuticals International compare with its peers?
Short answer
Kiniksa Pharmaceuticals International's score ranks 1st of 12 in the bounded comparison shown, against 11 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Kiniksa Pharmaceuticals International (KNSA) — this page | $93.53 | $7.35B | 98 |
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $28.35 Nov 19, 2026 | $5.89B | 74 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $2.34B | 70 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $4.69 Nov 18, 2026 | $2.33B | 47 5-pillar Nov 18, 2026 | |
| $26.70 Nov 18, 2026 | $13.4B | 35 5-pillar Nov 18, 2026 | |
| $19.88 Nov 19, 2026 | $22.8B | 35 5-pillar Nov 18, 2026 | |
| $8.73 Nov 18, 2026 | $3.27B | 30 5-pillar Nov 18, 2026 | |
| $50.37 Nov 19, 2026 | $6.15B | 21 5-pillar Nov 18, 2026 | |
| $16.05 Nov 19, 2026 | $2.23B | 16 5-pillar Nov 18, 2026 | |
| $221.38 Aug 21, 2026 | $5.61B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $74.00 – $115.00
- Consensus target
- $97.40
- Median target
- $99.00
Consensus record · Captured .
Measured against a quoted price of $93.53 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 60
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 27
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 61.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 61.5% Prior to period end Sep 30, 2026
- Reporting holders
- 312 Period end Sep 30, 2026
- Previous quarter · holders
- 276 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 7,487,391 |
| Blackrock, INC. | 2,943,674 |
| Baker Bros. Advisors LP | 2,834,643 |
| Rubric Capital Management LP | 2,813,469 |
| Tang Capital Management LLC | 2,259,889 |
Tracked investors
Which of the 16 named investors we follow held KNSA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KNSA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Kiniksa Pharmaceuticals International (KNSA)?
- 74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLC
- Kiniksa Pharmaceuticals International Insider Sold Shares Worth $1,111,531, According to a Recent SEC Filing
- Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference
- Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Kiniksa Pharmaceuticals International Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the KNSA research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for KNSA?
KNSA carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is KNSA a good stock to buy?
Stock Expert AI does not rate KNSA buy, sell or hold. Kiniksa Pharmaceuticals International, plc carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KNSA stock price today?
The last price recorded for Kiniksa Pharmaceuticals International, plc (KNSA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KNSA price target?
The analyst consensus price target for Kiniksa Pharmaceuticals International, plc (KNSA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for KNSA?
Kiniksa Pharmaceuticals, Ltd. faces several risks inherent in the biopharmaceutical industry. Clinical trial risks are significant, as unfavorable outcomes can delay or halt the development of pipeline candidates. Regulatory risks include potential delays or rejections in the drug approval process. Competition from established therapies and new entrants poses a threat to market share.
What are the key factors to evaluate for KNSA?
Kiniksa Pharmaceuticals International, plc (KNSA) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does KNSA data refresh on this page?
KNSA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KNSA's recent stock price performance?
Kiniksa Pharmaceuticals International, plc (KNSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (ARCALYST) generating revenue. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KNSA overvalued or undervalued right now?
The trailing P/E of Kiniksa Pharmaceuticals International, plc (KNSA) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 85 figures on this page — 1 from SEC filings and earnings calls, 76 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com